33,181 results match your criteria: "University Pierre & Marie Curie[Affiliation]"
Arch Med Res
December 2024
Department of Medical Oncology, Saint-Etienne University Hospital-Etienne, Saint-Etienne, France. Electronic address:
Background: The Patient Activation Measure-13 (PAM-13) assesses patients' ability to manage their healthcare. This systematic review aimed to summarize the relationship between the PAM-13 and patient characteristics, as well as program effectiveness.
Methods: A systematic literature search was conducted using the PubMed database and following the PRISMA guidelines.
Ann Dermatol Venereol
December 2024
Dermatology Department, Edouard Herriot University Hospital, Lyon, France; Dermatology Department, Croix-Rousse University Hospital, Hospices Civils de Lyon, Lyon, France.
Rheumatology (Oxford)
December 2024
Rheumatology Unit, Pitié-Salpêtrière University Hospital, AP-HP, Paris, France.
Introduction: The specificity of ultrasonography (US) for enthesitis in psoriatic arthritis (PsA) is unclear. The objective was to analyze the specificity of US enthesitis in Mode B and using Power Doppler (PD), for the diagnosis of PsA through a systematic review with meta-analysis.
Methods: Systematic review in PubMed 2010-June 2023, of studies of adult patients with confirmed PsA with or without a control group of non-PsA patients, reporting information on US enthesitis.
Aging Clin Exp Res
December 2024
National Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy.
Photochem Photobiol Sci
December 2024
Division of Photobiology and Photomedicine, Department of Dermatology, Henry Ford Health, Detroit, MI, USA.
Lancet Reg Health Eur
February 2025
Karolinska Institutet, Oncology/Pathology Department, Stockholm, Sweden.
Background: It is unclear whether some patients with high-risk breast cancer do not warrant adjuvant dose-dense chemotherapy due to small expected absolute benefit.
Methods: The phase 3 PANTHER trial (NCT00798070) compared adjuvant sequential epirubicin/cyclophosphamide (EC) and docetaxel (D) administered in either tailored dose-dense (tDD EC/D) or standard interval schedule (FEC/D) to patients with high-risk resected early breast cancer (n = 2003). We compared outcomes across key subgroups of interest, evaluated the performance of the online prognostication and treatment benefit estimation tool PREDICT and conducted a subpopulation treatment effect pattern plot (STEPP) analysis.
Front Immunol
December 2024
Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.
Background: Merkel cell carcinoma (MCC) is a rare but highly aggressive cutaneous malignancy. Immune checkpoint inhibition (ICI) with PD-(L)1 blockade has significantly improved treatment outcomes in metastatic disease. In patients with primary resistance to PD-(L)1 inhibition, a high overall response rate (ORR) of 50% to later-line ipilimumab plus nivolumab (IPI/NIVO) has been demonstrated.
View Article and Find Full Text PDFJ Oncol Pharm Pract
December 2024
Pharmacy, Léon Bérard Cancer Center, Lyon, France.
Objective: Despite significant advances in cancer treatment with targeted therapies and immunotherapies, cytotoxic chemotherapies are still extensively used. Potential cytotoxic contamination in preparing and administrating cytotoxics is still a major source of concern. Besides advanced protections including biological safety cabinets, work surface contamination needs to be continuously controlled to ensure that handling procedures and cleaning were appropriate.
View Article and Find Full Text PDFJ Clin Sleep Med
December 2024
Department of Surgery, Division of Plastic and Reconstructive Surgery, Section of Craniofacial Airway Orthodontics, Stanford University School of Medicine, Palo Alto, California.
Nat Immunol
January 2025
Faculty of Medicine, Clinic for Internal Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Disease, University Medical Center Freiburg, Freiburg, Germany.
The mechanisms underlying the efficacy of anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) therapy are incompletely understood. Here, by immune profiling responding PD-1CD8 T (T) cell populations from patients with advanced melanoma, we identified differential programming of T cells in response to combination therapy, from an exhausted toward a more cytotoxic effector program. This effect does not occur with anti-PD-1 monotherapy.
View Article and Find Full Text PDFInfluenza Other Respir Viruses
December 2024
Center of Excellence in Respiratory Pathogens (CERP), Hospices Civils de Lyon (HCL), Lyon, France.
Background: Respiratory Syncytial Virus (RSV) is a major health concern, particularly for infants. In France, Nirsevimab, a long-acting monoclonal antibody to prevent RSV-associated lower respiratory tract infections (LRTI) was available from September 2023. We described RSV-associated LRTI hospitalisations during the 2023-2024 season among infants younger than six months born at the Hospices Civils de Lyon (HCL), and evaluated the effectiveness of Nirsevimab against RSV-LRTI hospitalisation.
View Article and Find Full Text PDFNat Commun
December 2024
Mechanics and Genetics of Embryonic Development group, Institut Curie, Centre OCAV PSL Research University, Sorbonne University, CNRS UMR168 Physics of Cells and Cancer, Inserm, 11 rue Pierre et Marie Curie, 75005, Paris, France.
The development and origin of animal body forms have long been intensely explored, from the analysis of morphological traits during antiquity to Newtonian mechanical conceptions of morphogenesis. Advent of molecular biology then focused most interests on the biochemical patterning and genetic regulation of embryonic development. Today, a view is arising of development of multicellular living forms as a phenomenon emerging from non-hierarchical, reciprocal mechanical and mechanotransductive interactions between biochemical patterning and biomechanical morphogenesis.
View Article and Find Full Text PDFBone Marrow Transplant
December 2024
Department of Haematology, Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France.
The treatment of relapsed/refractory acute myeloid leukemia (AML) is associated with a dismal prognosis. The allogeneic hematopoietic cell transplantation (allo-HCT) is frequently performed as salvage therapy. Reduced intensity conditioning protocols have been developed with the aim of reducing the leukemia burden without increasing their toxicity.
View Article and Find Full Text PDFAppl Health Econ Health Policy
December 2024
Department of Market Strategy and Healthcare Financing, Erasmus University Medical Center, Rotterdam, The Netherlands.
Background And Objective: Rising healthcare costs challenge the financial sustainability of healthcare systems. Interventional pharmacoeconomics has emerged as a vital discipline to improve the cost-effective and sustainable use of drugs in clinical practice. However, current efforts are often fragmented, highlighting the need for an integrated hospital-wide approach.
View Article and Find Full Text PDFBMC Res Notes
December 2024
Faculty of Sport and Physical Education, University of Belgrade, Belgrade, Serbia.
Objective: Ultra-marathon running races are held as distance-limited or time-limited events, ranging from 6 h to 10 days. Only a few runners compete in 10-day events, and so far, we have little knowledge about the athletes' origins, performance, and event characteristics. The aim of the present study was to investigate the origin and performance of these runners and the fastest race locations.
View Article and Find Full Text PDFBMC Geriatr
December 2024
Department of Geriatrics and Aging Research, Center on Aging and Mobility, University of Zurich, c/o Stadtspital Zürich Waid Tièchestrasse 99, Zurich, 8037, Switzerland.
Background: Frailty is associated with multiple negative outcomes in geriatric trauma patients. Simultaneously, frailty assessment including physical measurements for weakness (grip strength) and slowness (gait speed) poses challenges in this vulnerable patient group. We aimed to compare the full 5-component Fried Frailty Phenotype (fFP) and a condensed model (cFP) without physical measurements, with regard to predicting hospital length of stay (LOS) and discharge disposition (DD).
View Article and Find Full Text PDFLung Cancer
December 2024
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Background: As for squamous (Sq)-NSCLC, Checkmate-017 trial showed a significant overall survival (OS) improvement in favor of Nivolumab (Nivo) over Docetaxel in 2nd-line. We hypothesized that anticipating Nivo use, as early switch maintenance after 1st-line chemotherapy (CHT), might have improved survival as compared to delayed 2nd-line treatment.
Methods: EDEN was an open-label, 2-arm, phase III study which randomized (1:1) stage IIIB/IV Sq-NSCLC pts non-progressive after 1st-line platinum-based CHT, to receive early Nivo as switch maintenance (Arm A) or standard best supportive care followed by 2nd-line Nivo at disease progression (Arm B).
Eur J Cancer
January 2025
University of Perugia, Unit of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy.
This guideline was developed in close collaboration with multidisciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF) and the European Organization for Research and Treatment of Cancer (EORTC). Recommendations for the diagnosis and treatment of melanoma were developed on the basis of systematic literature research and consensus conferences. Cutaneous melanoma (CM) is the most dangerous form of skin tumor and accounts for 90 % of skin cancer mortality.
View Article and Find Full Text PDFTransl Oncol
December 2024
Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany; Fleur Hiege Center for Skin Cancer Research, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. Electronic address:
Immune-checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, yet approximately half of patients do not respond to these therapies. Identifying prognostic biomarkers is crucial for treatment decisions. Our retrospective study assessed liquid biopsies and tumor tissue analyses for two potential biomarkers: danger-associated molecular pattern (DAMP) S100A8/A9 and its source, neutrophils.
View Article and Find Full Text PDFOncoimmunology
December 2025
Molecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain.
Health Qual Life Outcomes
December 2024
Department of Urology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, 1090, Austria.
Background: Electronic patient-reported outcomes (ePROs) have been shown to enhance healthcare quality by improving patient symptom management or quality of life (QoL). However, ePROs data for urothelial cancer (UC) patients receiving systemic therapies are scarce, and the application of ePROs in this patient cohort may need specific setups. This study tested the feasibility of ePROs for UC patients receiving systemic therapies in the outpatient clinic of a tertiary care center.
View Article and Find Full Text PDFCrit Care
December 2024
Department of Anesthesia and Intensive Care, Grenoble-Alpes University Hospital, Grenoble, France.
Background: Crystalloid-based fluid resuscitation has long been a cornerstone in the initial management of trauma-induced hemorrhagic shock. However, its benefit is increasingly questioned as it is suspected to increase bleeding and worsen coagulopathy. The emergence of alternative strategies like permissive hypotension and vasopressor use lead to a shift in early trauma care practices.
View Article and Find Full Text PDFBMC Public Health
December 2024
Department of Epidemiology and Public Health, Rue Juliette Wytsman 14, Sciensano, Brussels, 1050, Belgium.
Background: Multimorbidity is a rising public health concern. Indicators that address these complex health conditions are often exclusively devoted to physical diseases. Because of their high disease burden, mental health disorders ought to be considered as well.
View Article and Find Full Text PDFNPJ Breast Cancer
December 2024
Department of Medicine, University of Udine, 33100, Udine, Italy.
This study aimed to identify the clinico-pathological variables predictive of radiologic complete response (rCR) to first-line anti-HER2 therapy in patients with HER2-positive metastatic breast cancer. Patients were selected from the database of the GIM14 study and classified according to the best radiologic response obtained to first-line anti-HER2 therapy and upon time-to-treatment-discontinuation (TTD). A total of 545 patients were included in the analysis.
View Article and Find Full Text PDF